Drug intelligence / Profile preview

OT-202

Development stage: Phase 3
Lead developer: Ocumension Biotech
Modality: Small Molecules
Administration: Ophthalmic

Overview

OT-202 is a first-in-class, small molecule drug developed by Ocumension Therapeutics for the treatment of moderate to severe dry eye disease. Its mechanism of action is as a dual-targeted inhibitor of spleen tyrosine kinase (Syk) and vascular endothelial growth factor receptor 2 (VEGFR2), which achieves a synergistic effect in treating dry eye by inhibiting inflammatory responses. The drug has demonstrated positive safety and efficacy results in phase I and II clinical trials, with significant improvement in corneal staining scores compared to placebo. Phase III trials are anticipated[1][3][4][6].

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)SYK (Spleen Tyrosine Kinase)

Beyond the preview

Go deeper on OT-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OT-202.

Explore the full profile